What is SaNOtize Research & Development?
SaNOtize Research & Development is a pioneering pharmaceutical entity dedicated to the commercialization of nitric oxide-based medical technologies. The company's core innovation centers on a specialized nasal spray designed to provide a robust barrier against viral infections. By focusing on the intersection of biochemistry and clinical medicine, SaNOtize addresses critical gaps in current healthcare protocols.
The firm operates at the forefront of antimicrobial research, targeting both healthcare providers and strategic business partners. Their business model emphasizes rigorous clinical validation and the scalability of their therapeutic solutions, ensuring that their technology can be integrated into existing public health frameworks. With a focus on both safety and efficacy, SaNOtize is redefining the standards for preventative respiratory care.
How much funding has SaNOtize Research & Development raised?
SaNOtize Research & Development has raised a total of $26.5M across 2 funding rounds:
Series A
$2.5M
Series B
$24M
Series A (2020): $2.5M with participation from OurCrowd
Series B (2022): $24M led by ABC International, OurCrowd, and Horizons Ventures
Key Investors in SaNOtize Research & Development
Horizons Ventures
Horizons Ventures focuses on investing in deep science and technology aimed at advancing humanity towards a significantly improved future.
OurCrowd
OurCrowd is a company that offers an investment platform built for accredited investors and institutions to invest in startups, early-stage companies, and venture funds.
ABC International
Undisclosed investor participating in the funding round.
What's next for SaNOtize Research & Development?
With the recent infusion of capital, SaNOtize is well-positioned to scale its operations and advance its pipeline of medical solutions. The strategic roadmap likely includes the expansion of clinical trials, regulatory engagement across international markets, and the optimization of manufacturing processes to meet global demand. As the company moves beyond its current development phase, the focus will shift toward commercialization and the establishment of long-term partnerships with major healthcare distributors.
Investors are closely monitoring the company's progress as it navigates the complexities of the pharmaceutical regulatory landscape. The successful deployment of its nitric oxide technology could represent a paradigm shift in how viral protection is managed on a global scale, potentially securing SaNOtize a dominant position in the preventative medicine market.
